LSE:0AB6 - Hyloris Pharmaceuticals SA

Hyloris Pharmaceuticals S.A.
Sector: Health Care, Industry: Biotechnology

Add to Watchlist

•  Default
• New Watchlist

Yahoo Finance Note: This stock seems to be inactive

• Summary
• Financials
• Dividend
• Prices
• Posts
• User

Balance Sheet Cash Flow Income Statement Key Ratios Personalized Adjust Display Metrics

Show %	2019 Q1	2019 Q2	2020 Q1	2020 Q2	2021 Q2	2021 Q4	2022 Q2	2022 Q4	2023 Q2	Graph
Insider Holdings (%)	[friend]	[friend]	[friend]	[friend]	-	-	54.16% -	51.84% -4.3%	51.84% 0%
Net Margin	[friend]	[friend]	[friend]	[friend]	-	-	-	-	-
Gross Margin	[friend]	[friend]	[friend]	[friend]	-	-	-	-	-
Operating Margin	[friend]	[friend]	[friend]	[friend]	-	-	-	-	-
Total Revenue	[friend]	[friend]	[friend]	[friend]	838K 4310.5%	2.26M 169.5%	1.03M -54.3%	1.92M 85.7%	1.16M -39.5%
Total Assets	[friend]	[friend]	[friend]	[friend]	63.98M -10.9%	63.44M -0.8%	72.97M 15.0%	61.86M -15.2%	57.27M -7.4%
Total Liabilities	[friend]	[friend]	[friend]	[friend]	12.9M 6.2%	15.39M 19.2%	12.38M -19.5%	6.82M -44.9%	8.55M 25.4%
Total Equity	[friend]	[friend]	[friend]	[friend]	51.08M -14.4%	48.06M -5.9%	60.59M 26.1%	55.05M -9.1%	48.72M -11.5%
Operating CashFlow	[friend]	[friend]	[friend]	[friend]	-9.28M -	-1.97M -	-6.4M -	-6.75M -	-4.13M -
Beginning Cash Position	[friend]	[friend]	[friend]	[friend]	64.4M 474.3%	53.47M -17.0%	50.01M -6.5%	57.69M 15.3%	43.46M -24.7%
End Cash Position	[friend]	[friend]	[friend]	[friend]	53.47M -19.9%	50.01M -6.5%	57.69M 15.3%	43.46M -24.7%	39.16M -9.9%
Free Cash Flow	[friend]	[friend]	[friend]	[friend]	-9.44M -	-2.88M -	-6.61M -	-7.28M -	-4.37M -
Net Income (Cont Operations)	[friend]	[friend]	[friend]	[friend]	-8.24M -	-3.34M -	-4.94M -	-5.83M -	-6.63M -
Diluted Net Income	[friend]	[friend]	[friend]	[friend]	-8.24M -	-3.34M -	-4.94M -	-5.83M -	-6.63M -
Diluted EPS	[friend]	[friend]	[friend]	[friend]	-0.32 -	-0.13 -	-0.176 -	-0.208 -	-0.237 -
Return On Equity (%)	[friend]	[friend]	[friend]	[friend]	-	-	-	-	-
Return On Assets (%)	[friend]	[friend]	[friend]	[friend]	-	-	-	-	-